Abstract Number: 1558 • 2017 ACR/ARHP Annual Meeting
Changes in Blood Pressure with TNF Inhibitors for Psoriatic Arthritis
Background/Purpose: Psoriasis is a complex disorder with cutaneous and rheumatological manifestations affecting 2-3% of the population of the Western world. The prevalence of hypertension (HTN)…Abstract Number: 1571 • 2017 ACR/ARHP Annual Meeting
Bimekizumab Dual Inhibition of IL-17A and IL-17F Provides Evidence of IL-17F Contribution to Chronic Inflammation in Disease-Relevant Cells
Background/Purpose: IL-17A and IL-17F share structural homology and have similar biologic function.1 Although the contribution of IL-17A to immune-mediated inflammatory diseases has been widely reported,1,2…Abstract Number: 1577 • 2017 ACR/ARHP Annual Meeting
Deciphering the Role of the Tissue Microenvironment in Shaping the Immune Landscape in Psoriatic Arthritis
Background/Purpose: Psoriatic arthritis (PsA) occurs in a third of patients with psoriasis (Ps) and up to 30% of patients with PsA do not have an…Abstract Number: 36 • 2017 Pediatric Rheumatology Symposium
The Association of Obesity with Pediatric Psoriatic Arthritis
Background/Purpose: Obesity is associated with a significantly increased risk of inflammatory arthritis in adult patients with psoriasis. Obese adults with psoriatic arthritis (PsA) also…Abstract Number: 937 • 2016 ACR/ARHP Annual Meeting
Distal Interphalangeal Joint Erosions Assessed By HR-pQCT in Patients with Psoriatic Onycholysis
Background/Purpose: A third of cases of skin psoriasis are complicated by potentially incapacitating psoriatic arthritis (PsA). Nail psoriasis, especially onycholysis, is present in more than…Abstract Number: 2738 • 2016 ACR/ARHP Annual Meeting
The Effect of Pregnancy on Disease Activity Outcomes in Psoriatic Arthritis Patients
Background/Purpose : Psoriatic arthritis(PsA) often affects patients at a childbearing age. The relationship between pregnancy and PsA, in terms of pregnancy outcomes and its effect on…Abstract Number: 962 • 2016 ACR/ARHP Annual Meeting
No Increased Risk of Inflammatory Bowel Disease Among Secukinumab-Treated Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis: Data from 14 Phase 2 and Phase 3 Clinical Studies
Background/Purpose: Secukinumab, a fully human anti–interleukin-17A monoclonal antibody, has been evaluated and approved for the treatment of moderate to severe psoriasis, active psoriatic arthritis (PsA)…Abstract Number: 2765 • 2016 ACR/ARHP Annual Meeting
Practicing What We Preach? Do Psoriatic Arthritis Patients Treated at an Academic Medical Center Meet Caspar Criteria?
Background/Purpose: Psoriatic arthritis (PsA) is an autoimmune musculoskeletal disease with protean manifestations, and therefore can be difficult to diagnose. Although no diagnostic criteria are available, the…Abstract Number: 1293 • 2016 ACR/ARHP Annual Meeting
Utility of Extremity Magnetic Resonance Imaging (eMRI) without Contrast Enhancement in Detecting Preclinical Psoriatic Arthritis
Background/Purpose: Between 8-39% of patients with cutaneous psoriasis may develop psoriatic arthritis (PsA). Subclinical inflammatory joint disease in patients with psoriasis is common. i,ii This study…Abstract Number: 2769 • 2016 ACR/ARHP Annual Meeting
Does Gender Make a Difference in “Composite Psoriatic Disease Activity Index (CPDAI)” in Patients with Psoriatic Arthritis?
Background/Purpose: “Composite psoriatic disease activity index (CPDAI)” includes 5 domains: peripheral joints, skin, enthesitis, dactylitis, and spinal manifestations in psoriatic arthritis (PsA) which is a…Abstract Number: 1665 • 2016 ACR/ARHP Annual Meeting
Validation of Germ Line Epigenetic Variants Associated with Psoriatic Disease
Background/Purpose: Heritable epigenetic phenomena may play a role in the parent-of-origin effect observed in psoriasis and psoriatic arthritis (PsA). A previous epigenome-wide association study (EWAS)…Abstract Number: 3035 • 2016 ACR/ARHP Annual Meeting
Characterization of DC-STAMP+ T Cells, a CD3+CD4+ T Cell Subset Uniquely Present in Patients with Psoriatic Disease
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory joint disease that affects over 650,000 Americans. Bone damage occurs in half of these patients within the first…Abstract Number: 1684 • 2016 ACR/ARHP Annual Meeting
Updated Results for Serious Infections in Psoriasis Patients with Psoriatic Arthritis in the Psoriasis Longitudinal Assessment and Registry Study
Background/Purpose: To describe the rates of serious infections (SI) in psoriasis (PsO) pts with psoriatic arthritis (PsA) from PSOLAR, & assess risk with biologic therapy.…Abstract Number: 3185 • 2016 ACR/ARHP Annual Meeting
Sensitivity Analysis for the Smoking Paradox in the Development of Psoriatic Arthritis Among Psoriasis Patients
Background/Purpose: Smoking is a strong risk factor for psoriasis and psoriatic arthritis, but several studies have found that smoking is inversely associated with the risk…Abstract Number: 1685 • 2016 ACR/ARHP Annual Meeting
Updated Results for All-Cause Mortality and Malignancies in Psoriasis Patients with Psoriatic Arthritis in the Psoriasis Longitudinal Assessment and Registry Study
Background/Purpose: To describe characteristics & potential risk factors(including treatment exposure) for all-cause mortality & malignancies (excluding NMSC) in psoriasis (PsO) patients (pts) with psoriatic arthritis…